Market research
MRNS Marinus Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- 1.0667
- Dividend yield
- Not available
- Beta
- 1.26
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US56854Q1013
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- 1.0667
- Dividend yield
- Not available
- Beta
- 1.26
About
About Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MRNS discussion.
5 years, 4 months ago
Marinus Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 26.1% above its 200 day moving average.
From a valuation standpoint, the stock is 81.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 246.0.
Marinus Pharmaceuticals, Inc's total revenue rose by inf% to $2M since the same quarter in the previous year.
Its net income has dropped by 13.4% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 0.7% to $-16M since the same quarter in the previous year.
Based on the above factors, Marinus Pharmaceuticals, Inc gets an overall score of 3/5.